Superstring Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.46M Sell
115,234
-140,136
-55% -$1.59M 1.04% 25
2025
Q4
$2.09M Buy
255,370
+166,024
+186% +$1.91M 1.12% 27
2025
Q3
$1.07M Sell
89,346
-255,576
-74% -$2.69M 1.06% 29
2025
Q2
$3.5M Sell
344,922
-474,272
-58% -$3.18M 4.15% 12
2025
Q1
$4.57M Sell
819,194
-761,551
-48% -$6.66M 5.44% 8
2024
Q4
$12.8M Buy
1,580,745
+631,223
+66% +$5.79M 11.05% 1
2024
Q3
$9.73M Buy
+949,522
New +$9.39M 8.52% 5

Other funds holding ORIC

Superstring Capital Management's ORIC Position: Q1 2026 in Review

Superstring Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 55% in Q1 2026, selling an estimated $1.59M and leaving 115,234 shares worth $1.46M. The position accounts for 1.04% of the portfolio, ranked #25.

Superstring Capital Management first reported a position in ORIC in Q3 2024 and has held it in 7 quarters since. The position peaked at $12.8M in Q4 2024. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Superstring Capital Management held 115,234 shares of Oric Pharmaceuticals worth $1.46M as of Q1 2026.
  • Superstring Capital Management sold 140,136 Oric Pharmaceuticals shares in Q1 2026, an estimated $1.59M.
  • Oric Pharmaceuticals made up 1.04% of Superstring Capital Management's portfolio in Q1 2026, its #25 holding.
  • Superstring Capital Management first reported a position in Oric Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Superstring Capital Management's Oric Pharmaceuticals position peaked at $12.8M in Q4 2024.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.